Navigation Links
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/7/2008

ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference, which is being held November 10-12, 2008 at the New York Palace Hotel in New York, NY. Mr. Burns' presentation is scheduled for Tuesday, November 11, 2008 at 2:25 p.m. (local time).

Mr. Burns' presentation will be web cast and, as previously announced, will serve as the Company's third quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... BROOK, Ill., Dec. 7 The University ... (AMC) members for their achievements in UHC,s Supply ... organizations are noted for modeling best practices in ... http://www.newscom.com/cgi-bin/prnh/20091207/CG21708 ) ,, The winners were determined ... that includes contract portfolio participation and use of ...
(Date:12/6/2009)... factor, researchers say , , SUNDAY, Dec. 6 (HealthDay ... the main tumor to other parts of the body ... which may prove a promising target for new drugs ... Previous studies have shown that TGFb (transforming growth factor ... new study, a team from Cancer Research UK used ...
(Date:12/6/2009)... 6 Blood clotting, or coagulation, is ... a blood vessel is injured. Sometimes, however, clots ... obvious injury or do not dissolve naturally, a ... at the 51st Annual Meeting of the American ... using the anticoagulants aspirin and heparin with the ...
(Date:12/5/2009)... has shown in a phase 1/2 clinical trial ... treatment of patients newly diagnosed with multiple myeloma, a ... researchers from Dana-Farber Cancer Institute. , Partial responses or ... treated with the drug combination in the multi-center study, ... rate" in the phase 2 population, reports Paul G. ...
(Date:12/5/2009)... Leukemia and myeloproliferative disorders are serious and often ... 51st Annual Meeting of the American Society of ... diagnostic methods for patients suffering from acute promyelocytic ... and myelofibrosis that are based on a better ...
Breaking Medicine News(10 mins):Health News:Recognized Top Performers in UHC Supply Chain 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... journal publisher, is proud to be participating in a ... today by the Council of Science Editors. , The ... stimulate interest and debate on the crucial matters of ... both developed and developing countries will simultaneously publish papers ...
... says, , , MONDAY, Oct. 22 (HealthDay News) -- If you,re ... says a common device can determine whether someone is a ... used to ferret out people who hide a cigarette ... show patients what smoking is doing to their bodies, he ...
... Late-breaking results from the ENDEAVOR IV trial, presented at ... Research Foundation, show that the Endeavor zotarolimus-eluting stent met ... profile (equivalent rates of death, heart attack, and repeat ... , In addition, the Endeavor stent showed a ...
... Bayer Consumer Care announces,the availability of the ... Sinus), combining a long-lasting nasal decongestant with the,pain-relieving ... from,multiple sinus and pain symptoms. The combination ... in a recent survey of adults who suffer ...
... of,the nation,s leading information systems publications, has ranked ... top 500 innovators of information,technology. Highmark, which ... and,fourth in the insurance industry overall, moved up ... Tabor, Highmark,s senior vice president of information services ...
... than four percent lower, BLOOMINGTON, Minn., Oct. ... provide new evidence that members,who have health savings ... and are more engaged in seeking out more ... adjusted for illness burden, health,care costs were 4.4 ...
Other Medicine News:Health News:9 SAGE journals participate in global theme issue on poverty and human development 2Health News:Blood Test Catches Secret Smokers 2Health News:Blood Test Catches Secret Smokers 3Health News:ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent 2Health News:ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication 2Health News:ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication 3Health News:National Magazine Ranks Highmark 62nd Among Nation's 500 Most Innovative Users of Information Technology 2Health News:New Study Shows Lower Costs, Increased Consumer Engagement in Account-Based Health Plans 2
(Date:12/4/2009)... inexpensive computer tool that measures volume changes in the ... by a CT scanner can rule out non-cancerous ones ... true cancers with fewer, less expensive and less invasive ... diagnostic guidelines are described in a paper published yesterday ...
(Date:12/4/2009)... Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) announced that on ... Reorganization and related amended Disclosure Statement with the United States ... A hearing to consider the adequacy of the Disclosure Statement ... on the confirmation of the Plan scheduled for January 7, ...
(Date:12/4/2009)... 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... and webcast. Principal investigators will discuss the data ... as featured at the 51st American Society of Hematology ... 9:00 a.m. CT/10:00 a.m. ET on Monday, December 7, ...
Breaking Medicine Technology:European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex 28R 29 12913 1China Clean Energy Provides Business Update 12912 1China Clean Energy Provides Business Update 12912 2China Clean Energy Provides Business Update 12912 3US Farms Inc Showcasing Aloe Vera Product Line at Natural MarketPlace 2009 50872 1US Farms Inc Showcasing Aloe Vera Product Line at Natural MarketPlace 2009 50872 2
... able to stimulate insulin,release, TARRYTOWN, N.Y., March ... today results of two clinical,studies conducted in ... Gastroenterology and Hepatology,University Hospital Basel in Basel, ... peptide-1 (7-36 amide) (GLP-1) was to,establish the ...
... Survey Shows 89% of Patients Prefer Orapred ... 2007 /PRNewswire/ -- Alliant,Pharmaceuticals announced today survey ... sodium phosphate,orally disintegrating tablets) over liquid steroids.(1) ... survey involving more than,900 children (n=973), showed ...
Other Medicine Technology:Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 2Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 4Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 5Orapred ODT Tastes Good 2Orapred ODT Tastes Good 3
... an integral part of the enzymatic cascade ... as well as the degradation of Bradykinin. ... is primarily located in endothelial cells. ACE ... for sarcoidosis and myocardial infarction but is ...
... and quantitative evaluation of pancreatic b-cell function is ... post-diagnostic study of the natural history of diabetes ... as a guide to the correct choice of ... to assess b-cell function because of the ...
... hormone responsible for the control of glucose metabolism. ... the islets of Langerhans as the precursor, proinsulin, ... Both are secreted in equimolar amounts into ... is comprised of two polypeptide chains, the A-chain ...
... quantitative evaluation of pancreatic -cell function is not ... study of the natural history of diabetes mellitus, ... a guide to the correct choice of treatment. ... -cell function because of the large and variable ...
Medicine Products: